Skip to content
EntityQ25100640· pop 7· linked from 220 articles

pexidartinib

Sign in to save

Also known as PLX-3397, PLX3397

Pexidartinib, sold under the brand name Turalio, is a kinase inhibitor drug for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Pexidartinib blocks the activity of the colony-stimulating factor-1 receptor (CSF-1R).

~5 min read

Encyclopedic overview

4 sections
Contents
  • History
  • References
  • Further reading
  • External links

{{Infobox drug | drug_name = | INN = | type = | image = Pexidartinib.svg | image_class = skin-invert-image | width = | alt = | caption =

| pronounce = | tradename = Turalio | Drugs.com = | MedlinePlus = a619050 | licence_CA = | licence_EU = | DailyMedID = Pexidartinib | licence_US = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATCvet = | ATC_prefix = L01 | ATC_suffix = EX15

Excerpted from Wikipedia’s “pexidartinib” article, available under the CC BY-SA 4.0 licence.

Available in 7 languages

via Wikidata sitelinks · CC0